GLP-1

News

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

News

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.

News

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.

News

An alliance between Apple and FuturHealth will combine GLP-1 weight-loss treatment with the tech giant's Fitness+ subscription.

News

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

People completing a course of obesity medication, or completing a weight-management programme, need better support, according to NICE.